ANTIGEN DELIVERY SYSTEM

Abstract: Provided is a method of stimulating a class I-restricted immune response to a protein of interest or antigenic portion thereof in a host, as well as a protein delivery vehicle for use in the method. A nucleic acid molecule encoding the protein of interest or antigenic portion thereof is introduced into an avirulent Salmonella spp., such that the resulting Salmonella encodes a chimeric protein comprising the protein of interest or antigenic portion thereof and an injectable protein which is a target of a type III secretion system or an injectable portion thereof. This resulting Salmonella can be introduced into a host, in which the Salmonella will inject the chimeric protein into the cytosol of the cells of the host. The injection of the chimeric protein results in the stimulation of a class I-restricted immune response to the protein of interest or antigenic portion thereof in the host.

Description: ANTIGEN DELIVERY SYSTEM This application claims priority of U.S. Provisional Patent Application No. 60/047,955, filed May 29, 1997, and is a continuation-in-part of U.S. Patent Application Serial No. 08/987,691, filed December 9, 1997. The subject invention was made with support under Public Health Service Grant Nos . AI30492 and GM52543 of the National Institutes of Health. FIELD OF THE INVENTION The subject invention is directed generally to immune responses, and more particularly to a method of stimulating a class I-restricted immune response in a host and to a protein delivery system for use in such a method. BACKGROUND OF THE INVENTION Throughout this application various publications are referenced, many in parenthesis. Full citations for each of these publications are provided at the end of the Detailed Description. The disclosures of each of these publications in their entireties are hereby incorporated by reference in this application. Most infectious disease agents gain entrance to the host through a mucosal surface, therefore the first line of defense is the mucosal immune system. In fact, protection against many microorganisms better correlates with local than systemic immune responses (Galan et al . 1986; Galan and Timaney 1985) . The use of non- replicating antigens to stimulate mucosal immune responses has been hampered by the lack of adjuvants that effectively induce secretory immunity. Live, replicating antigens are known to better stimulate mucosal immunity partly because they tend to persist longer (Ganguly and Waldman 1980) . Avirulent strains of Salmonella typhimurium endowed with the ability to express cloned genes from other pathogens have been used to stimulate a generalized mucosal immune response against the recombinant virulence antigens (Doggett and Curtiss 1992; Curtiss et al . 1988; Curtiss et al . 1990; Galan et al . 1988) . This approach is based on the fact that S . typhimurium invades and proliferates in the gut- associated lymphoid tissue (GALT) (Carter and Collins 1974) and that antigens delivered into the GALT lead to an immune response at other mucosal sites (Cebra et al . 1976) . After oral ingestion, Salmonella typhimurium penetrates the cells of the intestinal epithelium (Takeuchi 1967) . Once internalized, Salmonella are translocated through the epithelial cells to the lamina propria where they are later taken up by macrophages. During the translocation process, Salmonella transit inside endocytic vesicles where they undergo limited replication. This is unlike other invasive pathogens, such as Shigella spp . or Listeria monocytogenes, which escape the endocytic vesicles shortly after internalization and actively replicate in the cell cytosol. The compartment in the eukaryotic cell in which a bacterium resides is very important when it is being considered as an antigen delivery vehicle, because its location will largely determine whether the antigen will be recognized in association with MHC class I or class II molecules. Antigens presented in the context of class I MHC molecules will predominantly induce cytotoxic T cells (T ctl ) , while antigens recognized in association with MHC class II molecules will be more likely to stimulate T helper cells (T H ) (Harding et al . 1988; Chain et al . 1988; Allen 1987) . This is of great importance in vaccine design since protection against different infectious agents requires different types of immune responses. Thus in general terms, T ctl 's play a key role in protection against most viral and some intracellular bacterial pathogens while T H ' s are more important in responses against exogenous antigens that enter the processing cells (expressing class II molecules) by endocytosis (Long and Jacobson 1989; Long 1989; Kaufman 1988) . It has been established that processing of exogenous antigens involves endocytosis, partial degradation within the endocytic vacuole, and binding to class II MHC molecules. Processing of class I-restricted antigens also appears to involve proteolysis and recognition of antigen-derived peptides bound to MHC class I molecules, although this processing is not secondary to endocytosis. Rather, antigens synthesized within host cells (e.g., viral proteins) , or antigens derived from intracellular bacteria that have the ability to exit the endocytic vacuole (e.g., Listeria monocytogenes and Shigella spp . ) , are processed and then preferentially associate with MHC class I molecules (Long and Jacobson 1989; Kaufman 1988) . Even though humoral (in particular mucosal) immune responses are an important part of the protective mechanisms against pathogens, it is clear that for efficient protection, cell-mediated immunity is often essential . This is particularly so when the pathogen in question is a virus or an intracellular bacterium. In many of these cases, class I restricted-immune responses are thought to be crucial for protection. This type of immune response is stimulated by proteins that are newly synthesized (e.g., viral antigens) or that otherwise gain access to the cytosol of the infected cell (e.g., Listeria antigens) . S . typhimurium has the ability to invade (enter) mammalian cells. Unlike other facultative intracellular pathogens such as Li steria or Shigella spp . , which gain access to the cytosol shortly after entry, Salmonella spp . remain inside the endocytic vesicle throughout their entire intracellular life cycle. Although there are some exceptions to this generalization (Aggarwal et al . 1990; Flynn et al . 1990), it appears that Salmonella is not very efficient at stimulating class I-restricted immune responses, which are known to be crucial for protection against viruses and a variety of intracellular pathogens (Gao et al . 1992; Yang et al . 1990) . This has been clearly demonstrated using avirulent Salmonella strains expressing different antigens from influenza virus. In a series of very elegant studies (Brett et al . 1993; Tite et al . 1990a; Tite et al . 1990b) , it was shown that mice vaccinated with avirulent strains of Salmonella expressing the influenza virus NP failed to mount a significant class I- restricted T cell response against the NP, although they successfully induced class II-restricted responses. On the contrary, class I-restricted responses against the NP were readily demonstrated in mice infected with the virus. As a consequence of this failure, recombinant Salmonella vaccine strains failed to protect mice against influenza virus challenge since in this model of NP immunization, protection is largely dependent on nucleoprotein-specific class I-restricted CD8 + cells. An essential feature of the pathogenesis of Salmonella spp . is their ability to stimulate a variety of host-cell responses (reviewed in Galan and Bliska 1996) . These responses are largely dependent on the type of cell engaged by the bacteria. For example, in non- phagocytic cells such as those of the intestinal epithelium, Salmonella spp . induce profound cytoskeletal rearrangements, membrane ruffling and macropinocytosis which ultimately result in bacteria internalization. In macrophages, on the other hand, Salmonella spp . induce programmed cell death (Chen et al . 1996). Essential for the stimulation of these responses is the function of a specialized protein secretion system encoded at centisome 63 of the bacterial chromosome (reviewed in Galan 1996) . This protein secretion system, termed type III, directs the export of a number of proteins, some of them with presumed effector function. Characteristic features of this protein secretion system, which has also been identified in several other animal and plant pathogenic bacteria, include: 1) the absence in the secreted proteins of a typical, cleavable, sec-dependent, signal sequence; 2) the requirement of several accessory proteins for the export process; 3) the export of the target proteins through both the inner and outer membranes; and 4) the requirement of activating extracellular signals for its full function (reviewed in Galan 1996) . Studies of pathogenic Yersinia spp . have established that a similar type III secretion apparatus directs the translocation into the host cells of a number of putative effector proteins such as the bacterial outer proteins YopE, YopH, YopM and YpkA (Rosqvist et al . 1994; Sory and Cornells 1994; Persson et al . 1995; Sory et al . 1995; Hakansson et al . 1996). Such translocation is thought to occur in a polarized manner in which proteins are transferred directly from the bacteria to the host cells without secretion into the infection medium. A notion has therefore emerged that protein translocation into host cells is perhaps the main function of this type of protein secretion system. This hypothesis is further supported by the observation that type III protein secretion systems have always been identified as essential determinants involved in intimate interactions of bacterial pathogens with their hosts (reviewed in Galan and Bliska 1996) . Several Salmonella proteins that are exported through this pathway have been identified although it is not known which, if any, of these proteins is translocated into host cells. A need exists for new methods for stimulating class I-restricted immune responses. SUMMARY OF THE INVENTION The subject invention addresses this need by providing a method for stimulating a class I-restricted immune response to a protein of interest or antigenic portion thereof in a host. The method comprises: introducing a nucleic acid molecule encoding a protein of interest or antigenic portion thereof into an avirulent Salmonella spp., the nucleic acid molecule being introduced so as to encode a chimeric protein comprising the protein of interest or antigenic portion thereof and an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and introducing the resulting Salmonella spp. into a host, wherein the resulting Salmonella spp. injects the chimeric protein into the cytosol of cells of the host thereby stimulating a class I-restricted immune response to the protein of interest or antigenic portion thereof in the host . The invention further provides a protein delivery vehicle which comprises: an avirulent Salmonella spp. encoding a chimeric protein, the chimeric protein comprising a protein of interest or an antigenic portion thereof and an injectable protein which is a target of a type III secretion system or an injectable portion thereof. Further provided is a chimeric protein which comprises: a first amino acid sequence of an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and a second amino acid sequence of a protein of interest or antigenic portion thereof introduced into the first amino acid sequence of the injectable protein or injectable portion thereof. Also provided is a chimeric nucleic acid molecule which comprises: a first nucleic acid sequence encoding an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and a second nucleic acid sequence encoding a protein of interest or antigenic portion thereof introduced into the first nucleic acid sequence of the injectable protein or injectable portion thereof, the second nucleic acid sequence being introduced so as to encode a chimeric protein comprising the protein of interest or antigenic portion thereof and the injectable protein or injectable portion thereof. BRIEF DESCRIPTION OF THE DRAWINGS These and other features and advantages of this invention will be evident from the following detailed description of preferred embodiments when read in conjunction with the accompanying drawings in which: Fig. 1 illustrates the insertion site of the influenza virus nucleoprotein epitope at the permissive site of SptP located between the two predicted independent domains of this protein; Figs. 2 and 3 illustrate antigen presentation by RMA or TAP-deficient RMA-S cells infected with S. typhimurium . RMA (Fig. 2) or RMA-S (Fig. 3) cells were infected with wild type, aroA, aroA sptP or sipD S . typhimurium strains bearing a plasmid expressing SptP- IVNP 366 _ 374 or SptP-LCMVNP 118 _ 126 prior to exposure to 12.164 hybridoma cells. The concentration of IL-2 secreted into the medium was determined by ELISA. When indicated, control RMA and RMA-S cultures were treated with 1 μM of IVNP 366 _ 374 peptide, LCMV NP 118 _ 126 peptide or were infected with influenza virus A/PR/8/34. Error bars depict SEM. Results are representative of three independent experiments; Fig. 4 illustrates the lysis of IVNP 366 _ 374 peptide- sensitized EL-4 cells by re-stimulated splenocytes from mice immunized with the aroA sptP S . typhimurium strain SB824 expressing SptP-IVNP 366 _ 374 , an irrelevant peptide (SptP-LCMVNP 118 _ 126 ) , or non-translocatable InvJ-IVNP 335 _ 498 . Control mice were vaccinated intraperitoneally with live influenza virus A/PR/8/34 or recombinant vaccinia virus expressing influenza nucleoprotein (Vaccinia NP) (Smith et al . 1987). Effector to target (E:T) ratios are indicated. Error bars depict SEM. Results are representative of three independent experiments; and Figs. 5 and 6 illustrate the immune response of mice immunized with avirulent S . typhimurium expressing SptP- LCMVNP 118 _ 126 . Fig. 5: Survival of vaccinated mice following LCMV intracerebral challenge inoculation. Groups of BALB/c mice were alternatively vaccinated with the avirulent aroA sptP S. typhimurium strain SB824 expressing SptP-LCMVNP 118 _ 126 , or SptP fused to an irrelevant epitope (SptP-IVNP 366 _ 374 ) , an avirulent S. typhimurium sipD " strain, defective in translocation but not in secretion of SptP-LCMVNP 118 _ 126 or mock vaccinated with broth. Fig. 6: Percent specific lysis by in vitro re-stimulated splenocytes from mice inoculated with aroA sptP S . typhimurium expressing SptP-LCMVNP 118 _ 126 or SptP fused to an irrelevant peptide (SptP-IVNP 366 _ 374 ) . Control mice were vaccinated by intraperitoneal inoculation with live LCMV. Effector to target (E:T) ratios are indicated. Error bars depict SEM. Results are representative of three independent experiments. DETAILED DESCRIPTION OF THE INVENTION As used herein, an "avirulent" Salmonella refers to a Salmonella which is not capable of causing disease in the host to which it is administered. As further used herein, a " Salmonella encoding" refers to a Salmonella which has nucleic acid therein which encodes the referenced protein, either as extrachromosomal nucleic acid or as nucleic acid incorporated into the genome of the Salmonella . The subject invention provides a method for stimulating a class I-restricted immune response to a protein of interest or antigenic portion thereof in a host. The method comprises: introducing a nucleic acid molecule encoding a protein of interest or antigenic portion thereof into an avirulent Salmonella spp., the nucleic acid molecule being introduced so as to encode a chimeric protein comprising the protein of interest or antigenic portion thereof and an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and introducing the resulting Salmonella spp. into a host, wherein the resulting Salmonella spp. injects the chimeric protein into the cytosol of cells of the host thereby stimulating a class I-restricted immune response to the protein of interest or antigenic portion thereof in the host. The invention further provides a protein delivery vehicle which comprises: an avirulent Salmonella spp. encoding a chimeric protein, the chimeric protein comprising a protein of interest or an antigenic portion thereof and an injectable protein which is a target of a type III secretion system or an injectable portion thereof. A host into which the protein delivery vehicle has been introduced is also provided. Suitable hosts include those in which a class I-restricted immune response is desirable, including, for example, humans. Further provided is a chimeric protein which comprises: a first amino acid sequence of an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and a second amino acid sequence of a protein of interest or antigenic portion thereof introduced into the first amino acid sequence of the injectable protein or injectable portion thereof. Also provided is a chimeric nucleic acid molecule which comprises: a first nucleic acid sequence encoding an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and a second nucleic acid sequence encoding a protein of interest or antigenic portion thereof introduced into the first nucleic acid sequence of the injectable protein or injectable portion thereof, the second nucleic acid sequence being introduced so as to encode a chimeric protein comprising the protein of interest or antigenic portion thereof and the injectable protein or injectable portion thereof. In each of the above embodiments of the invention, the protein of interest is selected based on the desirability of stimulating a class I-restricted immune response thereto. The many pathogens known to exist and yet to be discovered are examples of sources of "proteins of interest". For example, microbial proteins may be of interest. These include, for example, proteins from bacterial, viral, parasitic, and protozoan pathogens. This list is not inclusive, and the concept of the subject invention is equally applicable to any "protein of interest" as defined above. Furthermore, the particular injectable protein can be any protein which is a target of a type III secretion system (see Galan 1996; Rosqvist et al . 1994; Sory and Cornells 1994; Persson et al . 1995; Sory et al . 1995; Hakansson et al . 1996; and Galan and Bliska 1996 for discussions of type III secretion systems suitable for use in the subject invention) . Any type III secretion systems known to exist and yet to be discovered are examples of "type III secretion systems" in accordance with the subject invention. For example, currently known targets of bacterial type III secretion systems include the SptP, SipA, SipB, SipC, SipD, InvJ, SpaO, AvrA, and SopE proteins of Salmonella, the Yop and Ypk proteins of Yersinia (for example, YopE, YopH, YopM and YpkA) , the Ipa proteins of Shigella, and the ExoS proteins of Pseudomonas aeruginosa . Standard laboratory techniques known in the art of recombinant DNA and bacterial genetics can be used to construct chimeric proteins and to introduce a nucleic acid molecule encoding a protein of interest or antigenic portion thereof into an avirulent Salmonella spp. (see Sambrook et al . 1989) . One commonly used method for introducing nucleic acid molecules into a cell is through the use of a plasmid vector. The use of viral vectors such as bacteriophage is another example of a known method for introducing nucleic acid molecules into a cell (the bacteriophage is used to introduce nucleic acid molecules into a bacterial cell) . The engineered Salmonella spp. can be introduced into a host (in which a class I-restricted immune response is desired to the protein of interest) by any methods known in the art, including for example, oral infection or injection. Materials and Methods Bacterial strains, cell lines and cul ture condi tions Bacterial strains used are listed on Table 1 and were grown under conditions that allow expression of components and targets of the invasion-associated type III system (Collazo and Galan 1996) . Henle-407 cells were grown in Dulbecco's minimal essential medium (DMEM) containing 10% bovine calf serum. Immuno fluorescence staining Henle-407 cells were grown to semi-confluency in 12 mm round glass coverslips that had been previously treated with poly-L-lysine . Cells were infected with different S . typhimurium strains in Hank's balanced salt solution (HBSS) for varying times as indicated in each experiment at a multiplicity of infection (m.o.i.) of -25. When indicated, cytochalasin D was added to the cells 15 minutes before the infection at a concentration of 5 μg/ml. At this concentration, cytochalasin D effectively prevented bacterial internalization. In some experiments, gentamicin was added at a concentration of 100 μg/ml to eliminate extracellular bacteria. After infection, cells were washed three times with HBSS, fixed in 3.7% formaldehyde for 10 min, and permeabilized in 0.2% Triton X-100 in PBS for 2 minutes. After permeabilization, cells were washed three times with phosphate buffered saline containing 3% bovine serum albumin (PBS/BSA) and incubated for 30 min at room temperature with a 1:25 dilution in PBS/BSA of rabbit polyclonal antisera against SipB, SipC, AvrA, SptP and SopE . After washing three times with PBS/BSA, monolayers were incubated for 30 minutes at room temperature with fluorescein isothiocyanate (FITC) -labeled anti-rabbit IgG diluted 1:100 in PBS/BSA, washed three times with PBS and stained with DAPI (5 μg/ml) . Coverslips were mounted on glass slides with Vectashield mounting medium (Vector Labs, Inc.) and visualized under a Nikon Diaphot 300 fluorescence microscope or under a confocal microscope (Odyssey, Noran Instruments, Middletown WI) . Detection of translocated bacterial proteins in S . typhimurium- infected Henle-407 cells Semi-confluent Henle-407 cells were grown in 100 mm tissue culture plates and infected with different strains of S . typhimurium at an m.o.i. of 50 in 2.5 ml HBSS for 90 min. Prior to the infection, bacterial cultures were centrifuged and resuspended in HBSS to eliminate culture supernatant proteins. After infection, non-adherent bacteria were removed and cells were washed three times with HBSS. The infection supernatant was combined with the material from the washes and centrifuged at 8,000 g for 20 min. The pellet containing non-adherent bacteria was resuspended in 200 μl PBS (non-adherent bacteria fraction) . The supernatant was filtered through a 0.45 μm syringe filter (Gelman Sciences, MI) and proteins were precipitated by addition of 10% TCA and subsequent incubation at 4°C for 1 hr (infection medium fraction) . Infected cells were incubated for 30 minutes with DMEM containing 10% BCS and 100 μg/ml gentamicin to kill extracellular bacteria and subsequently washed thoroughly with HBSS. Cells were then treated with 30 μg/ml of proteinase K in HBSS for 15 min at 37°C in a C0 2 incubator to eliminate cell-surface associated Sip proteins. After proteinase K treatment, 3 ml of chilled HBSS containing 2mM PMSF were added. Cells detached during the proteinase treatment and were subsequently collected by low speed centrifugation (600 g for 10 minutes) and lysed in 1 ml of HBSS containing 0.1% Triton X-100 and ImM PMSF. The cell lysate was transferred to a microcentrifuge tube, treated with DNAse (10 μg/ml) and RNase (10 μg/ml) for 15 min at room temperature and centrifuged at 15,000 g for 10 minutes. The pellet was resuspended in PBS (Triton X-100 insoluble fraction) and the supernatant was filtered through a 0.45 μm syringe filter and proteins were precipitated in the presence of 10% TCA at 4°C (Triton X-100 soluble fraction) . Western blot analysi s Samples were separated in a 10% discontinuous SDS- PAGE, and transferred to nitrocellulose membranes as described (Collazo and Galan 1996) . SipB, SipC, AvrA, SptP and SopE proteins were detected by immunoblot analysis using monoclonal antibodies and enhanced chemiluminescence . For quantitation of the Sip proteins in the different cellular fractions, western blots were treated with monoclonal antibodies followed by alkaline phosphatase-labeled anti mouse antibody. Blots were developed by the addition of the fluorescence-emitting Attophos substrate (JBL, San Luis Obispo, CA) and scanned in a Molecular Dynamics Storm unit . The scanned membranes were quantified using the software ImageQuant version 1.1 (Molecular Dynamics) run on a Macintosh Power PC 8100 computer. EXAMPLE I SipB, SipC, SptP, AvrA and SopE are transloca ted into cul tured Henle-407 cells in an inv -dependent manner This experiment was designed to investigate whether infection of cultured intestinal Henle-407 cells with wild-type S . typhimurium would result in the translocation of SipB, SipC, SptP, AvrA or SopE which are targets of the invasion-associated type III secretion system (Kaniga et al . 1995a; Kaniga et al . 1995b). Cultured intestinal Henle-407 cells were infected with the S . typhimurium wild-type strain SL1344 or its isogenic mutant strain SB136 which carries a non-polar mutation in invA, a gene that encodes an essential component of the invasion-associated type III secretion system (Galan et al . 1992) . Two hours after infection, cells were fixed and processed for immunofluorescence staining with antibodies directed to SipB, SipC, AvrA, SptP and SopE as indicated in Materials and Methods. A fluorescence signal was apparent in samples infected with wild-type S . typhimurium and stained with the anti SipB, SipC, AvrA, SptP and SopE antibodies. Henle-407 cells infected with the invA mutant strain SB136 exhibited no cell SipC staining. Optical sectioning and confocal microscopy determined that SipC, AvrA, SipB, SopE and SptP were equally distributed throughout the cytoplasm of cells infected with wild-type bacteria. To further demonstrate the translocation of AvrA, SipB, SipC, SptP and SopE into infected cells, cultured Henle-407 cells were infected with Salmonella typhimurium . Two hours after infection, a biochemical fractionation of the infected cells was carried out and the presence of these proteins in the different fractions was investigated by Western Blot analysis as indicated in the Materials and Methods. AvrA, SipB, SipC, SptP and SopE were present in the infection media and Triton X-100 soluble and insoluble fractions of Henle-407 infected cells . These results indicate that SipB, SipC, SptP, SopE and AvrA are translocated into cultured Henle-407 cells and that such a translocation is dependent on the function of the type III protein secretion system encoded at centisome 63 on the S . typhimurium chromosome. EXAMPLE II Chimeric proteins between SptP, a target of the centisome 63 type III protein secretion system of Salmonella spp., and heterologous polypeptides are translocated into host cells Using recombinant DNA technology, a gene encoding a chimeric protein (termed SptP-NP) was constructed by introducing an oligonucleotide encoding a class I restricted epitope (SEQ ID N0:1: IASNENMETMESSTLELRS consisting of residues 365 through 384 of the influenza virus nucleoprotein) at residue 286 of the Salmonella SptP protein sequence. The sequence of the resulting chimeric protein (SptP-NP) is as follows (the influenza virus nucleoprotein epitope is depicted underlined and bold) : SEQ ID NO: 2 : MLKYEERKLNNLTLSSFSKVGVSNDARLYIAKENTDKAYVAPEKFSSKVLTWLGK MPLFKNTEWQKHTENIRVQDQKILQTFLHALTEKYGETAVNDALLMSRINMNKP LTQRLAVQI ECVKAADEGFINLIKSKDNVGVRNAALVIKGGDTKVAEKNNDVGA ESKQPLLDIALKGLKRTLPQLEQMDGNSLRENFQEMASGNGPLRSLMTNLQNLNK IPEAKQLNDYVTTLTNIQVGVARFSQWGTCGGEVERWVDKASTHELTQAVKKIHV IAKELKNVTEIASNENMETMESSTLELRSTELEKIEAGAPMPQTMSGPTLGLAR FAVSSIPINQQTQVKLSDGMPVPVNTLTFDGKPVALAGSYPKNTPDALEAHMKML LEKECSCLWLTSEDQMQAKQLPPYFRGSYTFGEVHTNSQKVSSASQGEAIDQYN MQLSCGEKRYTIPVLHVKNWPDHQPLPSTDQLEYLADRVKNSNQNGAPGRSSSD KHLPMIHCLGGVGRTGTMAAALVLKDNPHSNLEQVRADFRDSRNNRMLEDASQF VQLKAMQAQLLMTTAS A plasmid encoding SptP-NP was introduced into several strains of Salmonella typhimurium (listed in Table 1) and the resulting strains tested for their ability to direct the translocation of the chimeric protein into host cells. The translocation of the chimeric proteins was investigated by fluorescence microscopy and biochemical fractionation as described in Materials and Methods. Henle-407 cells were infected with strains of S . typhimurium encoding SptP-NP and after two hours of infection, cells were fixed and processed for immunofluorescence staining with a monoclonal antibody capable of detecting the chimeric protein. Infected cells showed intensive SptP-NP staining throughout the cell cytoplasm. Confocal microscopy established that the chimeric protein was distributed throughout the cell cytoplasm but was absent from the nucleus and plasma membranes of infected cells. These results indicate that S . typhimurium can translocate SptP-NP into host cells during infection. Similar studies were carried out with two additional chimeric proteins. One chimeric protein (termed SptP- LCM) was constructed by introducing an epitope of the lymphocytic coriomeningitis (LCM) virus (SEQ ID NO : 3 : RSERPQASGVYMGN) at residue 286 of the Salmonella SptP protein sequence. The sequence of the resulting chimeric protein (SptP-LCM) is as follows (the LCM epitope is depicted underlined and bold) : SEQ ID NO: 4 : MLKYEERKLNNLTLSSFSKVGVSNDARLYIAKENTDKAYVAPEKFSSKVLTWLGK MPLFKNTEWQKHTENIRVQDQKILQTFLHALTEKYGETAVNDALLMSRINMNKP LTQRLAVQITECVKAADEGFINLIKSKDNVGVRNAALVIKGGDTKVAEKNNDVGA ESKQPLLDIALKGLKRTLPQLEQMDGNSLRENFQEMASGNGPLRSLMTNLQNLNK IPEAKQLNDYVTTLTNIQVGVARFSQWGTCGGEVERWVDKASTHELTQAVKKIHV IAKELKNVTERSERPQASGVYMGNTELEKIEAGAPMPOTMSGPTLGLARFAVSS IPINQQTQVKLSDGMPVPVNTLTFDGKPVALAGSYPKNTPDALEAHMKMLLEKEC SCLWLTSEDQMQAKQLPPYFRGSYTFGEVHTNSQKVSSASQGEAIDQYICNCLRG KAYTSVLHVKNWPDHQPLPSTDQLEYLADRVKNSNQNGAPGASSSDKHLPMIHC LAGVGRTGTMAGGLVLKDNLIVIWSRYVQIRITT The other chimeric protein (SptP-NPc) was constructed by fusing the first 173 amino acids of SptP with residues 335 through 498 of the influenza virus nucleoprotein. The sequence of the resulting chimeric protein (SptP-NPc) was as follows (the influenza virus nucleoprotein portion is depicted underlined and bold) : SEQ ID NO: 5: MLKYEERKLNNLTLSSFSKVGVSNDARLYIAKENTDKAYVAPEKFSSKVLTWLGK MPLFKNTEWQKHTENIRVQDQKILQTFLHALTEKYGETAVNDALLMSRINMNKP LTQRLAVQITECVKAADEGFINLIKSKDNVGVRNAALVIKGGDTKVAEKNNDVGA ESKOPLLSAAFEDLRVSSFIRGTKWPRGKLSTRGVQIASNENMETMESST LELRSRYWAIRTRSGGNTNQQRASSGQISIQPTFSVORNLPFDRPTIMAA FTGNTEGRTSDMRTEIIRLMESARPEDVSFQGRGVFELSDEKAASPIVPSF DMSNEGSYFFGDNAEEYDN When expressed in various strains of S . typhimurium both chimeric proteins (SptP-LCM and SptP-NPc) were translocated into host cells. EXAMPLE III Salmonella strains expressing chimeric proteins between SptP and influenza nucleoprotein peptide sequences can present a nucleoprotein epitope via the class I pathway in vi tro To examine the ability of the different Salmonella strains (SL 1344 and χ3625) expressing SptP-Np and SptP- NPc to present the influenza virus nucleoprotein epitope via the class I presenting pathway in vi tro, an assay was used based on the induction of IL-2 production in the T cell hybridoma 1192 upon presentation of the NP366-374 peptide in the context of class I D b molecules by the EL4 murine lymphoma cell line. EL4 cells (~6xl0 7 ) , grown in Dulbecco's modified MEM with 10% fetal bovine serum, 10 mM HEPES, 5xl0 "5 M 2 -mercaptoethanol and without antibiotics (DMEM-10) , were alternatively infected with 6xl0 9 c.f.u. of the different strains of S . typhimurium (constructed as described in Example II) expressing either SptP-NP or SptP-NP. Infections were carried out as described (Kaniga et al . 1996). After infection, non- internalized or adhered bacteria were removed by washing, and cells further incubated in the presence of 100 μg/ml of gentamicin for 1 hour. A volume of 0.1 ml of DMEM-10 containing 2xl0 5 EL4 cells infected with Salmonella were distributed into each well of 96-well plates in quadruplicate. To each well 1x10 s 1192 T cell hybridoma effector cells (clones 12.164 or 7.9.3.28) in 0.1 ml of DMEM-10 were added. Plates were then incubated for 10 hours at 37°C, 100 μl of supernatant fluid removed from each well, divided in two aliquots, placed in individual wells of a 96 well plate and stored at -20°C for subsequent IL-2 quantitation. The presence of IL-2 in the cell culture media aliquots was determined using the IL-2 -dependent cell line CTLL-2 (ATCC TIB-214) as follows. To the thawed plates containing the test samples (EL4 + 1192 supernatants) 5xl0 4 CTLL-2 cells in 100 μl of DMEM-10 were added and the plates incubated for 16-18 hours at 37°C. CTLL-2 proliferation in response to cytokines was measured by the MTT dye reduction assay. The reduction of the yellow MTT to a blue formazan is proportional to the number and metabolic rate of the CTLL-2 cells. To this end, 20 μl of a 5mg/ml sterile solution of MTT was added to all wells and the plates incubated for 6 hours at 37°C. The reduced MTT formazan was solubilized with acid isopropanol and the absorbance of each well was measured in an ELISA plate reader equipped with a 570 nm filter. The response was compared to a standard curve prepared by adding purified recombinant IL-2 to parallel cultures of CTLL-2 cells. Influenza virus PR8-infected EL4 cells (multiplicity of infection of 10) and influenza virus nucleoprotein peptide NP366-374 served as positive controls. EL4 cells infected with the same S . typhimurium strains expressing the influenza virus nucleoprotein not fused to the SptP protein (NP) and therefore unable to be delivered into host cells served as negative controls. The results are shown in Table 2. EXAMPLE IV Additional chimeric proteins are translocated into host cells A chimeric form of SptP that carries a Class-I restricted epitope consisting of residues 366 through 374 from the influenza virus nucleoprotein (IVNP 366 _ 374 ) found to be immunodominant in mice of the H-2 b haplotype (Vitiello et al . 1996: Rotzschke et al . 1990) was constructed. The epitope was introduced at a permissive site of SptP located between the two predicted independent domains of this protein (Fig. 1) (Kaniga et al. 1996; Fu and Galan 1998). Plasmid pSB762, which encodes a chimeric protein consisting of SptP fused to a region of the influenza virus NP comprising residues 366 through 374 (SEQ ID NO: 6: ASNENMETM) of the influenza virus nucleoprotein, was constructed by inserting a double stranded oligonucleotide (SEQ ID NO: 7: 5'- AAATTGCTTCCAATGAAAACATGGAGACTATGGAATCAAGTACCCTTGAACTGAGAA GCA-3') into the unique PvuII site of sptP. A double stranded oligonucleotide (SEQ ID NO: 8: 5'- AACGTAGCGAACGGCCGCAAGCATCAGGCGTTTATATGGGAAATA-3' ) was inserted into the unique PvuII site of sptP to construct plasmid pSB775 which encodes a protein fusion between SptP and residues 118 through 126 of the LCMV nucleoprotein. Both plasmids are derived from the low copy plasmid pWSK-II (Wang and Kushner 1991) . Random expression of the chimeric protein is driven by the plac promoter. Plasmid pSB776, which encodes a fusion between the first 179 amino acids of InvJ and residues 335 through 498 of the influenza virus nucleoprotein was constructed by polymerase chain reaction. This plasmid is derived from the low copy plasmid pYA292 (Galan et al . 1990) and expression of the chimeric protein is driven by the plac promoter. Strain SB824 was constructed by introducing the sptP::kan mutant allele from strain SB237 (Kaniga et al . 1996; Fu and Galan 1998) into the AaroA strain SL3261 (Hoiseth and Stocker 1981) via P22HTint transduction. The chimeric SptP-IVNP 366 _ 374 protein was secreted into the culture supernatant of both wild-type S . typhimurium and the isogenic avirulent aroA sptP mutant strain SB824 at levels indistinguishable from those of wild-type SptP. Furthermore, both strains efficiently delivered Spt- IVNP 366 _ 374 into the cytosol of infected cultured epithelial cells. In contrast, and as expected, the isogenic S . typhimurium sipD mutant strain SB221 failed to translocate the chimeric protein into the host-cell cytosol although it was able to secrete SptP-IVNP 366 _ 374 to the infection medium. SipD is essential for type III protein translocation into host cells although it is completely dispensable for protein secretion (Kaniga et al . 1996; Fu and Galan 1998; Kaniga et al . 1995). Similar results were obtained when a different epitope derived from the lymphocytic choriomeningitis virus nucleoprotein (LCMVNP 118 . 126 ) was introduced at the same site of SptP. These results indicate that SptP can serve as a "molecular courier" to deliver foreign peptides of immunological interest to the cytoplasm of target cells. EXAMPLE V Salmonella strains expressing the additional chimeric proteins can present a nucleoprotein epitope via the class I pathway in vi tro The ability of wild type, aroA and aroA sptP S . typhimurium expressing the chimeric protein SptP-IVNP 366 _ 374 to deliver the influenza nucleoprotein (NP) epitope to a Class I-restricted antigen presenting pathway was then examined. Murine RMA thymoma cells (H-2 b ) were infected with the different S . typhimurium strains and the ability of the infected cells to present the influenza NP epitope to the Class I-restricted T-cell hybridoma 12.164 was assessed by measuring its IL-2 secretory response (Deckhut et al . 1993; Ljunggren and Karre 1985). RMA or RMA-S cells (C57/BL/6J mouse lymphoma) , cultured without antibiotics in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS) , were used as antigen presenting cells (APC) (Deckhut et al . 1993; Ljunggren and Karre 1985) . APC cells were infected with S . typhimurium strains grown as previously described (Collazo and Galan 1996) . Approximately 3 X 10 8 bacterial colony forming units were used to infect 10 7 APC cells in a 3 ml volume of DMEM at 37°C for 2 hrs . Control APC cells were prepared by infection with 10 75 plaque forming units (PFU) of influenza A virus (strain A/PR/8/34) or incubation in 1 μM IVNP 366 _ 374 synthetic peptide (sequence: SEQ ID NO: 6: ASNENMETM) for 2 hrs . APC cells subjected to the different procedures were subsequently washed and incubated for 1 hr in DMEM containing 100 μg/ml gentamicin. APC cells (2 X 10 6 /ml) suspended in DMEM supplemented with FBS and gentamicin (50 μg/ml) were distributed in quadruplicate 100 μl cultures in 96-well plates. Influenza NP-specific T-cell hybridoma 12.164 cells (2 X 10 5 /100 μl/well) were added to the treated RMA or RMA-S cultures (Deckhut et al . 1993; Ljunggren and Karre 1985) . Cultures were incubated for 44 hrs at 37°C and the culture medium harvested to determine the IL-2 concentration in the supernatant by a capture ELISA assay using rat anti-mouse IL-2 monoclonal antibodies (Pharmingen) . As shown in Fig. 2, the RMA thymoma cells infected with S . typhimurium strains expressing SptP-IVNP 366 _ 374 were efficiently recognized by the epitope-specific T-cell hybridoma. Antigen presentation was strictly dependent on the cytosolic delivery of the epitope by the S . typhimurium type III system, as RMA cells infected with a sipD ~ mutant strain, which is capable of secreting SptP- IVNP 366 _ 374 but is unable to deliver it into the cell cytosol, failed to stimulate the T-cell hybridoma (Fig. 2) . Furthermore, S. typhimurium strains expressing the carboxy terminal half of the influenza virus NP fused to InvJ (InvJ-IVNP 335 _ 498 ) , a protein substrate of the type III system that is secreted but it is not translocated into host cells (Collazo and Galan 1996; Collazo et al . 1995), failed to present antigen in infected RMA cells (Fig. 2) . These results indicate that S . typhimurium is capable of delivering foreign epitopes to the Class I antigen presenting pathway via proteins translocated by the type III secretion system. Peptides delivered to the cytosol by S . typhimurium required a functional peptide transporter system (TAP) for their transfer to the endoplasmic reticulum and loading by Class I molecules since TAP2 -defective RMA-S mutant cells (Attaya et al . 1992) infected by S. typhimurium SptP-INVP 36S _ 374 were markedly impaired in their capacity to stimulate the T-cell hybridoma when compared to the wild-type RMA cells (Fig. 3) . This result provides independent evidence that peptides displayed at the RMA cell surface by Class-I molecules occupied a cytosolic compartment prior to their transfer into the endoplasmic reticulum. EXAMPLE VI Salmonella strains expressing the additional chimeric proteins can induce protective Class I-restricted cytotoxic T- lymphocytes in vivo The potential of avirulent S . typhimurium strains expressing SptP-IVNP 366 _ 374 to induce cytotoxic T- lymphocytes (CTL) in vivo was then examined. C57/BL/6J mice orally inoculated with an avirulent S . typhimurium sptP aroA mutant strain expressing SptP-IVNP 366 _ 374 developed CTL precursors which, upon re-stimulation, lysed target cells infected with influenza virus or loaded with the synthetic peptide NP 366 _ 374 (Fig. 4) . Cytotoxic T lymphocytes (CTL) specific for influenza or LCMV were quantitated as described elsewhere (Wunderlich and Shearer 1991) . Briefly, spleen cells from two or three mice were pooled and re-stimulated in vitro for 5 days by co-culture with irradiated syngeneic splenocytes infected with A/PR/8/34 influenza virus at a multiplicity of infection of 3 , or treated with 1 μM of a synthetic peptide with sequence derived from the LCMVNP 118 _ 126 (sequence: SEQ ID NO:9: RPQASGVYM) . EL-4 (H-2 b ) and P815 (H-2 d ) target cells were prepared by incubation with 1 μM IVNP 366 _ 374 , or LCMVNP 118 _ 126 peptides and followed by labeling with 0.15 mCi of [ 51 Cr] -Na chromate . To set cultures with a range of effector to target (E:T) ratios, appropriate numbers of effector cells were combined with constant numbers of target cells in quadruplicate cultures using 96-well plates. Target lysis was assessed by 51 Cr release after co-cultivation for 4 hours. Target lysis was calculated from the standard formula: [ (Experimental release - Spontaneous release) / (Maximum release - Spontaneous release)] X 100. Maximum release was determined by Triton X-100 cell lysis. Spontaneous release was always <10% of maximum release. Data are presented as % specific lysis, with the % lysis of unsensitized target cells subtracted from the % lysis of cognate peptide sensitized target cells. In contrast and consistent with the in vitro antigen presentation results, mice inoculated with Salmonella expressing either the irrelevant epitope SptP-LCMVNP 118 _ 126 or non-translocatable InvJ-IVNP 335 _ 498 failed to stimulate CTL directed to influenza virus epitopes (Fig. 4) . Thus, cytoplasmic targeting of the type III system hybrid substrates dictates the outcome of the Class I-restricted response to a foreign epitope: pronounced CTL responses were induced by the S . typhimurium mutant strain expressing SptP-IVNP 366 _ 374 but not by the strain expressing the non-translocated InvJ-IVNP 335 _ 498 chimeric protein. To assess the ability of the type Ill-mediated S . typhimurium antigen delivery system to induce protective Class I-restricted CTL, murine lymphocytic choriomeningitis virus (LCMV) infection was chosen because it is the most reliable model to assess the role of CTL in protection against viral disease (Klavinskis et al . 1989; Whitton et al . 1989). In this model, intracerebral inoculation with LCMV results in a lethal choriomeningitis which can be prevented by a single clonal population of LCMV-specific CTL (Klavinskis et al . 1989; Whitton et al . 1989). BALB/c mice immunized with the aroA sptP S . typhimurium mutant strain expressing SptP-LCMVNP 118 _ 126 were completely protected against lethal intracerebral challenge with a virulent strain of LCMV (Fig. 5) . C57BL/6J or BALB/c mice were fasted for 6 hrs and given 100 μl of 10% bicarbonate orally one hour prior to intragastric inoculation with 1-2 X 10 8 CFU of appropriate live S . typhimurium strains grown as described (Collazo and Galan 1996) . Intragastric inoculation was repeated at 4- and 6- weeks after the initial inoculation. Spleens were removed two weeks after the last bacterial inoculation to evaluate CTL activity in three mice from each group. To determine protective immunity, groups of 6-8 vaccinated mice were inoculated intracerebrally with 10 LD 50 of LCMV strain Armstrong. For control purposes, mice were inoculated intraperitoneally with 10 7 - 5 PFU of influenza virus A/PR/8/34, 10 6 PFU of vaccinia influenza NP or 10 4 PFU of LCMV strain Armstrong four weeks prior to immunity assessment . In contrast, mice immunized with S . typhimurium aroA mutant strain expressing an irrelevant epitope (SptP- IVNP 366 _ 374 ) succumbed to the same challenge (Fig. 5). Consistent with the hypothesis that protection was mediated by an H-2 restricted immune response, the same S . typhimurium aroA mutant strain expressing SptP- LCMVNP 118 _ 126 failed to protect C57/BL/6J mice against an identical challenge with LCMV. Furthermore, protection required cytosolic delivery of the epitope by the type III secretion system as vaccination with a S . typhimurium sipD ~ strain, defective in translocation but not in secretion of SptP-LCMVNP 118 _ 126 failed to protect mice against lethal LCMV infection (Fig. 5) . Induction of protective immunity in mice by Salmonella vaccination was correlated with the presence of LCMV-specific CTL (Fig. 6) . These results show that delivery of epitopes through the S . typhimurium type III secretion system results in efficient stimulation of Class-I restricted protective antiviral immune responses. This approach expands the use of S . typhimurium as a carrier of heterologous antigens to vaccinate against infections in which this type of response is crucial for protection (Hackett 1993; Karen et al . 1997) . In addition, avirulent S . typhimurium expressing tumor-specific antigens allow the use of this system for the treatment of neoplastic diseases by induction of cancer cell-specific Class I- restricted CTL (Schmidt et al . 1997; Ossevoort et al . 1995; Schlom et al . 1996). Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow. Table 1. Bacterial strains used in this study. Strains Relevant Genotype Reference or source S . typhimuri urn SL1344 rpsL hisG (Hoiseth and Stocker 1981) SB136 rpsL hisG invA : : aρhT (Galan et al . 1992) SB225 rpsL hisG sipA : :aphT (Kaniga et al . 1995) SB169 rpsL hisG sipB : :aphT (Kaniga et al . 1995) SB220 rpsL hisG sipC: :aphT (Kaniga et al . 1995) SB221 rpsL hisG sipD : :aphτ (Kaniga et al . 1995) SB237 rpsL hisG sptP : :aphT (Kaniga et al . 1996) X3625 rpsL hisG aroA : : Tnl O (Hoiseth and Stocker 1981) Table 2. Class I-restricted antigen presentation following challenge of antigen presenting cells with S . typhimurium expressing SptP-NP. Challenge Hybridoma IL-2 (pg) PR8 12.164 800±70 PR8 7.9.3.2. 4167±320 NP366-374 12.164 213±10 NP366-374 7.9.3.2. 1250±80 SL1344 (SptP-NP) 12.164 172±10 SL1344 (SptP-NP) 7.9.3.2. 300±18 SL1344 (NP) 12.164 <20* SL1344 (NP) 7.9.3.2. <20* χ3625 (SptP-NP) 12.164 314±30 χ3625 (NP) 12.164 <20* *This values were considered negative as they were below the detection range of the assay REFERENCES Aggarwal, A., et al . , J Exp Med 172:1083-1090 (1990) . Allen, P.M., Immunol Today 8:270-273 (1987). Attaya, M., et al . , Nature 355:647 (1992) . Brett, S.J., et al . , J Immunol 150:2869-2884 (1993) . Carter, P. and Collins, F., J " Exp Med 139:1189-1203 (1974) . Cebra, J.J., et al . , Cold Spring Harbor Symp Quant Biol 41:201-215 (1976) . Chain, B.M., et al . , Immunol Rev 106:33-58 (1988) . Chen, L.M., et al . , Mol Mi crobiol 21:1101-1115 (1996) . Chen, Y., et al . , EMBO J 15 : 3853-3860 (1996) . Collazo, CM., and Galan, J.E., Mol Microbiol 24:747 (1996) . Collazo, C. and Galan, J.E., Infect Immun 64:3524-3531 (1996) . Collazo, CM., et al . , Mol Microbiol 15:25 (1995). Curtiss, R. , et al . , in Virul ence Mechani sms of Bacterial Pathogenesis , R. Roth, Ed. (American Society for Microbiology, Washington, D.C., 1988) pp. 311-328. Curtiss, R., et al . , Res Mi crobiol 141:797-805 (1990) . Deckhut, A., et al., J Immunol 151:2658 (1993). Doggett, T.A. and Curtiss, R. , Adv Exp Med Biol 327:165- 173 (1992) . Flynn, J.L., et al . , Molec Microbiol 4:2111-2118 (1990) . Fu, Y., and Galan, J.E., Mol Microbiology 27:359 (1998) . Galan, J.E., Mol ecular Microbiol 20:263-271 (1996) . Galan, J.E. and Bliska, J.B., Ann Rev Cell Dev Biol 12 :219-253 (1996) . Galan, J.E., et al . , in Proc V Interna t Cong Equine Infect Dis , D. Powell, Ed. (University of Kentucky Press, 1988) pp. 34-40. Galan, J.E., et al . , Gene 94:29 (1990). Galan, J.E., et al . , J Bacteriol 17:4338-4349 (1992) . Galan, J.E., et al . , Infection & Immuni ty 54:202-206 (1986) . Galan, J.E. and Timoney, J.F., Infection & Immuni ty 47:623-628 (1985) . Ganguly, R. and Waldman, R., Prog Allergy 27:1-68 (1980). Gao, X.M., et al . , Infect Immun 60:3780-3789 (1992) . Hackett, J., Curr Opin Biotechnol 4:611 (1993) . Hakansson, S., et al . , Mol Mi crobiol 20:593-603 (1996) . Harding, C.V., et al . , Immunol Rev 106:77-92 (1988) . Hoiseth, S.K. and Stocker, B.A., Na ture 291:238-239 (1981) . Kaniga, K. , et al . , J Bacteriol 177:7078-7085 (1995a). Kaniga, K. , et al . , J Bacteriol 177:3965-3971 (1995b). Kaniga, K. , et al . , Mol Mi crobiol 21:633-641 (1996) . Karem, K.L., et al . , J Gen Virol 78:427 (1997). Kaufman, S.H.E., Immunol Today 9:168-174 (1988). Klavinskis, L.S., et al . , J Immunol 143:2013 (1989) . Ljunggren, H.G., and Karre, K. , J Exp Med 162:1745 (1985) . Long. E.O. and Jacobson, S., Immunol Today 10:45-48 (1989) . Long, E.O., Immunol Today 10 :232-234 (1989). Ossevoort, M.A. , et al . , J Immunother Emphasis Tumor Immunol 18:86 (1995) . Persson, C, et al . , Molecular Mi crobiol 18:135-150 (1995) . Rosqvist, R., et al . , EMBO J 13 : 964-972 (1994) . Rotzschke, O., et al . , Nature 348:252 (1990) . Sambrook, et al . , Molecular Cloning: A Laboratory Manual , 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989) . Schlom, J. , et al . , Breast Cancer Res Treat 38:27 (1996) . Schmidt, W., et al . , Proc Natl Acad Sci USA 94:3262 (1997) . Smith, G.L., et al . , Virology 160:336 (1987) . Sory, M.-P., et al . , Proc Na tl Acad Sci USA 92:11998- 12002 (1995) . Sory, M.-P. and Cornells, G.R., Molec Mi crobiol 14:583- 594 (1994) . Takeuchi, A . , Am J Pa thol 50:109-136 (1967) . Tite, J.P., et al . , Immunology 70 : 540-546 (1990a) . Tite, J.P., et al . , Immunology 71 : 202-207 (1990b) . Vitiello, A., et al . , J Immunol 157:5555 (1996) . Wang, R.F., and Kushner, S., Gene 100:195 (1991) . Whitton, J.L., et al . , J Virol 63:4303 (1989) . Wunderlich, J., and Shearer, G. , In Current Protocols in Immunology, J. Coligan, et al . , Eds., John Wiley and Sons, New York (1991) . Yang, D.M. , et al . , J Immunol 145:2281-2285 (1990) . SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: The Research Foundation of State University of New York (ii) TITLE OF INVENTION: ANTIGEN DELIVERY SYSTEM (iii) NUMBER OF SEQUENCES: 9 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Jaeckle Fleischmann & Mugel, LLP (B) STREET: 39 State Street (C) CITY: Rochester (D) STATE: New York (E) COUNTRY: USA (F) ZIP: 14614-1310 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/047,955 (B) FILING DATE: 29-MAY-1997 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/987,691 (B) FILING DATE: 09-DEC-1997 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Braman, Susan J (B) REGISTRATION NUMBER: 34,103 (C) REFERENCE/DOCKET NUMBER: 87653.98R154 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 716-262-3640 (B) TELEFAX: 716-262-4133 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 336 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 : Met Leu Lys Tyr Glu Glu Arg Lys Leu Asn Asn Leu Thr Leu Ser Ser 1 5 10 15 Phe Ser Lys Val Gly Val Ser Asn Asp Ala Arg Leu Tyr lie Ala Lys 20 25 30 Glu Asn Thr Asp Lys Ala Tyr Val Ala Pro Glu Lys Phe Ser Ser Lys 35 40 45 Val Leu Thr Trp Leu Gly Lys Met Pro Leu Phe Lys Asn Thr Glu Val 50 55 60 Val Gin Lys His Thr Glu Asn lie Arg Val Gin Asp Gin Lys lie Leu 65 70 75 80 Gin Thr Phe Leu His Ala Leu Thr Glu Lys Tyr Gly Glu Thr Ala Val 85 90 95 Asn Asp Ala Leu Leu Met Ser Arg lie Asn Met Asn Lys Pro Leu Thr 100 105 110 Gin Arg Leu Ala Val Gin lie Thr Glu Cys Val Lys Ala Ala Asp Glu 115 120 125 Gly Phe lie Asn Leu lie Lys Ser Lys Asp Asn Val Gly Val Arg Asn 130 135 140 Ala Ala Leu Val lie Lys Gly Gly Asp Thr Lys Val Ala Glu Lys Asn 145 150 155 160 Asn Asp Val Gly Ala Glu Ser Lys Gin Pro Leu Leu Ser Ala Ala Phe 165 170 175 Glu Asp Leu Arg Val Ser Ser Phe lie Arg Gly Thr Lys Val Val Pro 180 185 190 Arg Gly Lys Leu Ser Thr Arg Gly Val Gin lie Ala Ser Asn Glu Asn 195 200 205 Met Glu Thr Met Glu Ser Ser Thr Leu Glu Leu Arg Ser Arg Tyr Trp 210 215 220 Ala lie Arg Thr Arg Ser Gly Gly Asn Thr Asn Gin Gin Arg Ala Ser 225 230 235 240 Ser Gly Gin lie Ser lie Gin Pro Thr Phe Ser Val Gin Arg Asn Leu 245 250 255 Pro Phe Asp Arg Pro Thr lie Met Ala Ala Phe Thr Gly Asn Thr Glu 260 265 270 Gly Arg Thr Ser Asp Met Arg Thr Glu lie lie Arg Leu Met Glu Ser 275 280 285 Ala Arg Pro Glu Asp Val Ser Phe Gin Gly Arg Gly Val Phe Glu Leu 290 295 300 Ser Asp Glu Lys Ala Ala Ser Pro lie Val Pro Ser Phe Asp Met Ser 305 310 315 320 Asn Glu Gly Ser Tyr Phe Phe Gly Asp Asn Ala Glu Glu Tyr Asp Asn 325 330 335 (2) INFORMATION FOR SEQ ID NO : 2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : lie Ala Ser Asn Glu Asn Met Glu Thr Met Glu Ser Ser Thr Leu Glu 1 5 10 15 Leu Arg Ser (2) INFORMATION FOR SEQ ID NO : 3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 564 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Met Leu Lys Tyr Glu Glu Arg Lys Leu Asn Asn Leu Thr Leu Ser Ser 1 5 10 15 Phe Ser Lys Val Gly Val Ser Asn Asp Ala Arg Leu Tyr lie Ala Lys 20 25 30 Glu Asn Thr Asp Lys Ala Tyr Val Ala Pro Glu Lys Phe Ser Ser Lys 35 40 45 Val Leu Thr Trp Leu Gly Lys Met Pro Leu Phe Lys Asn Thr Glu Val 50 55 60 Val Gin Lys His Thr Glu Asn lie Arg Val Gin Asp Gin Lys lie Leu 65 70 75 80 Gin Thr Phe Leu His Ala Leu Thr Glu Lys Tyr Gly Glu Thr Ala Val 85 90 95 Asn Asp Ala Leu Leu Met Ser Arg lie Asn Met Asn Lys Pro Leu Thr 100 105 110 Gin Arg Leu Ala Val Gin He Thr Glu Cys Val Lys Ala Ala Asp Glu 115 120 125 Gly Phe He Asn Leu He Lys Ser Lys Asp Asn Val Gly Val Arg Asn 130 135 140 Ala Ala Leu Val He Lys Gly Gly Asp Thr Lys Val Ala Glu Lys Asn 145 150 155 160 Asn Asp Val Gly Ala Glu Ser Lys Gin Pro Leu Leu Asp He Ala Leu 165 170 175 Lys Gly Leu Lys Arg Thr Leu Pro Gin Leu Glu Gin Met Asp Gly Asn 180 185 190 Ser Leu Arg Glu Asn Phe Gin Glu Met Ala Ser Gly Asn Gly Pro Leu 195 200 205 Arg Ser Leu Met Thr Asn Leu Gin Asn Leu Asn Lys He Pro Glu Ala 210 215 220 Lys Gin Leu Asn Asp Tyr Val Thr Thr Leu Thr Asn He Gin Val Gly 225 230 235 240 Val Ala Arg Phe Ser Gin Trp Gly Thr Cys Gly Gly Glu Val Glu Arg 245 250 255 Trp Val Asp Lys Ala Ser Thr His Glu Leu Thr Gin Ala Val Lys Lys 260 265 270 He His Val Xaa He Ala Lys Glu Leu Lys Asn Val Thr Glu He Ala 275 280 285 Ser Asn Glu Asn Met Glu Thr Met Glu Ser Ser Thr Leu Glu Leu Arg 290 295 300 Ser Thr Glu Leu Glu Lys He Glu Ala Gly Ala Pro Met Pro Gin Thr 305 310 315 320 Met Ser Gly Pro Thr Leu Gly Leu Ala Arg Phe Ala Val Ser Ser He 325 330 335 Pro He Asn Gin Gin Thr Gin Val Lys Leu Ser Asp Gly Met Pro Val 340 345 350 Pro Val Asn Thr Leu Thr Phe Asp Gly Lys Pro Val Ala Leu Ala Gly 355 360 365 Ser Tyr Pro Lys Asn Thr Pro Asp Ala Leu Glu Ala His Met Lys Met 370 375 380 Leu Leu Glu Lys Glu Cys Ser Cys Leu Val Val Leu Thr Ser Glu Asp 385 390 395 400 Gin Met Gin Ala Lys Gin Leu Pro Pro Tyr Phe Arg Gly Ser Tyr Thr 405 410 415 Phe Gly Glu Val His Thr Asn Ser Gin Lys Val Ser Ser Ala Ser Gin 420 425 430 Gly Glu Ala He Asp Gin Tyr Asn Met Gin Leu Ser Cys Gly Glu Lys 435 440 445 Arg Tyr Thr He Pro Val Leu His Val Lys Asn Trp Pro Asp His Gin 450 455 460 Pro Leu Pro Ser Thr Asp Gin Leu Glu Tyr Leu Ala Asp Arg Val Lys 465 470 475 480 Asn Ser Asn Gin Asn Gly Ala Pro Gly Arg Ser Ser Ser Asp Lys His 485 490 495 Leu Pro Met He His Cys Leu Gly Gly Val Gly Arg Thr Gly Thr Met 500 505 510 Ala Ala Ala Leu Val Leu Lys Asp Asn Pro His Ser Asn Leu Glu Gin 515 520 525 Val Arg Ala Asp Phe Arg Asp Ser Arg Asn Asn Arg Met Leu Glu Asp 530 535 540 Ala Ser Gin Phe Val Gin Leu Lys Ala Met Gin Ala Gin Leu Leu Met 545 550 555 560 Thr Thr Ala Ser (2) INFORMATION FOR SEQ ID NO : 4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4 : Arg Ser Glu Arg Pro Gin Ala Ser Gly Val Tyr Met Gly Asn 1 5 10 (2) INFORMATION FOR SEQ ID NO : 5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 529 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 : Met Leu Lys Tyr Glu Glu Arg Lys Leu Asn Asn Leu Thr Leu Ser Ser 1 5 10 15 Phe Ser Lys Val Gly Val Ser Asn Asp Ala Arg Leu Tyr He Ala Lys 20 25 30 Glu Asn Thr Asp Lys Ala Tyr Val Ala Pro Glu Lys Phe Ser Ser Lys 35 40 45 Val Leu Thr Trp Leu Gly Lys Met Pro Leu Phe Lys Asn Thr Glu Val 50 55 60 Val Gin Lys His Thr Glu Asn He Arg Val Gin Asp Gin Lys He Leu 65 70 75 80 Gin Thr Phe Leu His Ala Leu Thr Glu Lys Tyr Gly Glu Thr Ala Val 85 90 95 Asn Asp Ala Leu Leu Met Ser Arg He Asn Met Asn Lys Pro Leu Thr 100 105 110 Gin Arg Leu Ala Val Gin He Thr Glu Cys Val Lys Ala Ala Asp Glu 115 120 125 Gly Phe He Asn Leu He Lys Ser Lys Asp Asn Val Gly Val Arg Asn 130 135 140 Ala Ala Leu Val He Lys Gly Gly Asp Thr Lys Val Ala Glu Lys Asn 145 150 155 160 Asn Asp Val Gly Ala Glu Ser Lys Gin Pro Leu Leu Asp He Ala Leu 165 170 175 Lys Gly Leu Lys Arg Thr Leu Pro Gin Leu Glu Gin Met Asp Gly Asn 180 185 190 Ser Leu Arg Glu Asn Phe Gin Glu Met Ala Ser Gly Asn Gly Pro Leu 195 200 205 Arg Ser Leu Met Thr Asn Leu Gin Asn Leu Asn Lys He Pro Glu Ala 210 215 220 Lys Gin Leu Asn Asp Tyr Val Thr Thr Leu Thr Asn He Gin Val Gly 225 230 235 240 Val Ala Arg Phe Ser Gin Trp Gly Thr Cys Gly Gly Glu Val Glu Arg 245 250 255 Trp Val Asp Lys Ala Ser Thr His Glu Leu Thr Gin Ala Val Lys Lys 260 265 270 He His Val Xaa He Ala Lys Glu Leu Lys Asn Val Thr Glu Arg Ser 275 280 285 Glu Arg Pro Gin Ala Ser Gly Val Tyr Met Gly Asn Thr Glu Leu Glu 290 295 300 Lys He Glu Ala Gly Ala Pro Met Pro Gin Thr Met Ser Gly Pro Thr 305 310 315 320 Leu Gly Leu Ala Arg Phe Ala Val Ser Ser He Pro He Asn Gin Gin 325 330 335 Thr Gin Val Lys Leu Ser Asp Gly Met Pro Val Pro Val Asn Thr Leu 340 345 350 Thr Phe Asp Gly Lys Pro Val Ala Leu Ala Gly Ser Tyr Pro Lys Asn 355 360 365 Thr Pro Asp Ala Leu Glu Ala His Met Lys Met Leu Leu Glu Lys Glu 370 375 380 Cys Ser Cys Leu Val Val Leu Thr Ser Glu Asp Gin Met Gin Ala Lys 385 390 395 400 Gin Leu Pro Pro Tyr Phe Arg Gly Ser Tyr Thr Phe Gly Glu Val His 405 410 415 Thr Asn Ser Gin Lys Val Ser Ser Ala Ser Gin Gly Glu Ala He Asp 420 425 430 Gin Tyr He Cys Asn Cys Leu Arg Gly Lys Ala Tyr Thr Ser Val Leu 435 440 445 His Val Lys Asn Trp Pro Asp His Gin Pro Leu Pro Ser Thr Asp Gin 450 455 460 Leu Glu Tyr Leu Ala Asp Arg Val Lys Asn Ser Asn Gin Asn Gly Ala 465 470 475 480 Pro Gly Ala Ser Ser Ser Asp Lys His Leu Pro Met He His Cys Leu 485 490 495 Ala Gly Val Gly Arg Thr Gly Thr Met Ala Gly Gly Leu Val Leu Lys 500 505 510 Asp Asn Leu He Val He Trp Ser Arg Tyr Val Gin He Arg He Thr 515 520 525 Thr (2) INFORMATION FOR SEQ ID NO : 6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : Ala Ser Asn Glu Asn Met Glu Thr Met 1 5 (2) INFORMATION FOR SEQ ID NO : 7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7 : AAATTGCTTC CAATGAAAAC ATGGAGACTA TGGAATCAAG TACCCTTGAA CTGAGAAGCA 60 (2) INFORMATION FOR SEQ ID NO : 8 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: AACGTAGCGA ACGGCCGCAA GCATCAGGCG TTTATATGGG AAATA 45 (2) INFORMATION FOR SEQ ID NO : 9 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9 : Arg Pro Gin Ala Ser Gly Val Tyr Met 1 5

Claims: What Is Claimed Is: 1. A method of stimulating a class I-restricted immune response to a protein of interest or antigenic portion thereof in a host, said method comprising: introducing a nucleic acid molecule encoding a protein of interest or antigenic portion thereof into an avirulent Salmonella spp., the nucleic acid molecule being introduced so as to encode a chimeric protein comprising the protein of interest or antigenic portion thereof and an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and introducing the resulting Salmonella spp. into a host, wherein the resulting Salmonella spp. injects the chimeric protein into the cytosol of cells of the host thereby stimulating a class I-restricted immune response to the protein of interest or antigenic portion thereof in the host. 2. The method of claim 1 wherein the protein of interest comprises a microbial protein. 3. The method of claim 1 wherein the injectable protein is an injectable protein of Salmonella . 4. The method of claim 1 wherein the injectable protein is an injectable protein of Yersinia . 5. The method of claim 1 wherein the injectable protein is an injectable protein of Shigella . 6. The method of claim 1 wherein the injectable protein is a target of a type III secretion system of a bacteria. 7. A protein delivery vehicle comprising: an avirulent Salmonella spp. encoding a chimeric protein, the chimeric protein comprising a protein of interest or an antigenic portion thereof and an injectable protein which is a target of a type III secretion system or an injectable portion thereof. 8. The protein delivery vehicle of claim 7 wherein the protein of interest comprises a microbial protein. 9. The protein delivery vehicle of claim 7 wherein the injectable protein is an injectable protein of Salmonella . 10. The protein delivery vehicle of claim 7 wherein the injectable protein is an injectable protein of Yersinia . 11. The protein delivery vehicle of claim 7 wherein the injectable protein is an injectable protein of Shigella . 12. The protein delivery vehicle of claim 7 wherein the injectable protein is a target of a type III secretion system of a bacteria. 13. A host into which the protein delivery vehicle of claim 7 has been introduced. 14. A chimeric protein comprising: a first amino acid sequence of an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and a second amino acid sequence of a protein of interest or antigenic portion thereof introduced into the first amino acid sequence of the injectable protein or injectable portion thereof. 15. The chimeric protein of claim 14 wherein the protein of interest comprises a microbial protein. 16. The chimeric protein of claim 14 wherein the injectable protein is an injectable protein of Salmonella . 17. The chimeric protein of claim 14 wherein the injectable protein is an injectable protein of Yersinia . 18. The chimeric protein of claim 14 wherein the injectable protein is an injectable protein of Shigella . 19. The chimeric protein of claim 14 wherein the injectable protein is a target of a type III secretion system of a bacteria. 20. A chimeric nucleic acid molecule comprising: a first nucleic acid sequence encoding an injectable protein which is a target of a type III secretion system or an injectable portion thereof; and a second nucleic acid sequence encoding a protein of interest or antigenic portion thereof introduced into the first nucleic acid sequence of the injectable protein or injectable portion thereof, the second nucleic acid sequence being introduced so as to encode a chimeric protein comprising the protein of interest or antigenic portion thereof and the injectable protein or injectable portion thereof. 21. The chimeric nucleic acid molecule of claim 20 wherein the protein of interest comprises a microbial protein. 22. The chimeric nucleic acid molecule of claim 20 wherein the injectable protein is a target of any type III secretion system of any bacteria. 23. The chimeric nucleic acid molecule of claim 20 wherein the injectable protein is an injectable protein of Yersinia . 24. The chimeric nucleic acid molecule of claim 20 wherein the injectable protein is an injectable protein of Shigella . 25. The chimeric nucleic acid molecule of claim 20 wherein the injectable protein is a target of a type III secretion system of a bacteria.

Inventors: GALAN JORGE E, GALAN, JORGE, E.
Applicants: UNIV NEW YORK, THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Application year: 1998
Main classification: A61K48
IPC codes: A61K39, A61K48, C07K14, C12N1, C12N15